Posted by Michael Wonder on 25 Aug 2022
Chugai obtains regulatory approval for Polivy for additional indication of previously untreated diffuse large B-cell lymphoma
24 August 2022 - The approval is based on the results from a Phase 3 POLARIX study in patients with previously untreated DLBCL.
Chugai Pharmaceutical announced that it obtained regulatory approval today from the Ministry of Health, Labour and Welfare for the anti-cancer agent/antimicrotubule binding anti-CD79b monoclonal antibody Polivy intravenous infusion 30 mg and 140 mg [polatuzumab vedotin] for an additional indication of treatment of patients with previously untreated diffuse large B-cell lymphoma.
